Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADX-2191 in Primary Vitreoretinal Lymphoma
NCT07402876Phase 3Recruiting
- Sponsor
- Aldeyra Therapeutics
- Start
- Feb 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ADX-2191 in primary vitreoretinal lymphoma (PVRL), sponsored by Aldeyra Therapeutics. Started Feb 2026; status: recruiting.
02
Drugs
ADX-2191
03
Conditions
primary vitreoretinal lymphoma (PVRL)
Beyond the preview
Go deeper on NCT07402876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07402876.